Trial Profile

Randomized Phase II of TARCEVA (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Carmustine; Temozolomide
Indications Glioblastoma
Focus Therapeutic Use

Most Recent Events

16 Feb 2009 Status changed from active, no longer recruiting to completed.
09 Feb 2009 Primary endpoint 'Progression free survival rate' has not been met.
23 Sep 2007 Results were presented at ECCO 2007.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com